

Test utilization— are you driving the bus, chased by the bus or under it?



Debbi Tiffany MSED, MLS(ASCP)^{CM} SC^{CM} SLS^{CM}

Director of Laboratory Services
SwedishAmerican Health System
Rockford, Illinois

Official disclaimer and introduction

- Who am I and why am I presenting this topic?



We all know it's out there.....

*The Future of Lab
Utilization Management--
Are Lab Formularies the
Answer?*

Utilization
Management 2013

**Optimal
Utilization of
Laboratory
Testing**

Managing physician
use of laboratory tests.


“Choosing
Wisely” Program
Wants to
Encourage
Better Utilization
of Clinical
Pathology
Laboratory Tests

*Pulling back
the reins on
superfluous
testing*

LABORATORY
UTILIZATION
IMPROVEMENTS:
APPROACHES,
OUTCOMES AND
IMPACT

An administrative
intervention to improve
the utilization of
laboratory tests within a
university hospital

How labs are taming
test utilization





Where do I start?

“It is the direction and not the magnitude which is to be taken into consideration.”

Thomas Paine



Source: <http://9teen87spostcards.blogspot.com/>


High level view

- What is my menu?
- Where are these tests being done?
- What instrument platforms do I have?
- Who is ordering them?
- How much are they costing me?
- Can we do anything better?
 - TAT
 - Pricing
 - Workflow

Tracking what you do

- Year to year comparisons
 - Top 25 in house and referred tests
 - Look for change in volume or order pattern change
 - Physician or practice changes
 - Effect of CPOE, LIS, or HIS changes
 - Evidence based medicine or practice guideline changes and updates
 - Viability of keeping a test in-house


Lipoprotein (a)




REVIEWING SEND OUT TESTS



Referred Testing Volumes




Referred Testing Expense



Reviewing your send out tests—things you can do yourself

- Year to year comparisons
 - Top 25 referred tests
 - Look for change in volume or order pattern change
 - Physician or practice changes
 - Effect of CPOE, LIS, or HIS changes
 - Evidence based medicine or practice guideline changes and updates
 - **Can I do any of these tests myself?**

Hepatitis B Core Ab, Total




Intervention #1

Intervention #2

Hepatitis B Core Ab, Total

	send out cost	in house cost
	\$9.92	\$3.30
FY12 volume	398	398
total cost	\$3,948.16	\$1,313.40
Savings		\$2,634.76

25-OH Vitamin D



25-OH Vitamin D

	send out cost	in house cost
	\$16.25	\$8.95
FY11 volume	13,149	13,149
total cost	\$213,671.25	\$117,683.55
savings		\$95,987.70

Evidence based medicine or practice guidelines

- The “trend” of celiac testing
- Following guidelines




Celiac serology—who, what, where, and can I do better?

- Celiac testing being ordered by family practice, internal medicine, and mid-level providers like PA's and APN's and not just gastroenterologists
- Analysis of testing provided by a specialized laboratory (Laboratory "P") indicated a battery of tests being used for celiac serology testing
- Other national reference laboratories were using reflex testing in response to published guidelines

Celiac serology—shotgun versus reflex

	Lab P	Lab A
	\$231.98	\$33.16
FY12 volume	182	182
total cost	\$42,220.36	\$6,035.12
savings		\$36,185.24



Reviewing send out tests—now you need some expert help

- How do I compare to other labs?
 - Do we order more/less/same?
- Are we ordering
 - Inappropriate tests?
 - Outdated tests?
 - Duplicate or tests with limited use?



What to look at and why?


- Mis-utilization/underutilization
 - APC resistance and Factor V Leiden
- Suboptimal/overutilization
 - Ova and Parasite testing
- Outdated or inappropriate testing
 - H. pylori serology testing
 - Aldolase

APC and Factor V Leiden

- “For factor V Leiden testing, functional testing (i.e. activated protein C (APC) resistance) is clinically equivalent to DNA testing as an initial test and is less costly.”
- “Abnormal APC resistance test results can be followed up with PCR testing for confirmation and to distinguish homozygotes from heterozygotes.”

Screen with APC

Factor V Leiden



	FY08	FY09	FY10	FY11	FY12	FY13
Volume	245	325	302	269	262	242

Intervention #1

Intervention #2

Where are we now?

- Still too many Factor V Leiden being sent out
 - Inpatients
 - “shotgun orders” by certain providers
 - One oncologist
 - Multiple locum tenens hospitalists
- What now?
 - CPOE order screen/order set redesign
 - Pathologist intervention with certain providers
 - Bring the test in-house to better scrutinize orders?

Ova & parasite testing


- First referred out in FY09
 - Staffing
 - Expertise
- No criteria for specimen submission or pre-screening
 - *“If you have a specimen, it gets sent out”*



Based on consultation.....

- Specimen criteria set up for sending out O&P beginning June 2011 and communicated by pathologist responsible for Microbiology
 - If patient is immunocompromised
 - If patient has a travel history
- If criteria not met, in-house Giardia and Cryptosporidia testing performed and specimen held 30 days
 - This information is communicated in report
- In 1st year
 - 57% reduction in unnecessary testing
 - Approximately \$38,000 in savings

O&P




We have a problem

Outdated or inappropriate testing

- *H. pylori* serology testing is not recommended per evidence based medicine
- Better methods available
 - Breath test
 - Stool antigen
- SAH appeared to order more than “normal” compared to other labs

H. pylori IgM



- Drill down revealed inappropriate ordering across the system and not isolated to any one clinic or provider
- Communication regarding more appropriate testing (newsletter, specific individual letters, electronic “Dr. Hub” posting) not effective at changing ordering behavior
- All *H. pylori* serology tests removed from computerized order entry system and letters issued announcing discontinuation as of June 2012
 - Link to appropriate testing guidelines provided in letters

Aldolase

- Considered outdated and of little clinical utility
- Drill down on orders
 - Single location
 - PA's and APN's
- Tried communication strategy regarding use of CK as an alternative




FUTILITY

No matter how hard you try, you will fail.

Still incomplete intervention

Aldolase—my nemesis



Success factors

- Data, data, and more data
- Willingness to dig into data
 - Get it to “talk to me”
- Real world savings
- Support from our reference lab (on-call pathologist, subject experts, online resources)
- “Can-do” attitude from lab supervisors to bring testing in-house if needed
- Properly motivated and informed physicians

Strive for progress
not for perfection.

Thank You!